title: [TRPV1 in neuropathic pain: from animal models to therapeutical prospects].
abstract: Since its cloning in 1997, functional and structural studies of TRPV1 have led to an improvement in our understanding of the mechanisms that underlie the transduction of noxious thermal and mechanical stimuli by sensory neurons. Because of its role in inflammatory processes and nociceptive pathways, TRPV1 has become an important target for neuropathic pain relief. Models of painful small-fiber sensory neuropathy were developed and several laboratories have progressed in the conception of TRPV1 agonists and antagonists. Patch and cream containing capsaicin, the most famous TRPV1 agonist, are commercialized to relieve neuropathic pain. Others agonists and TRPV1 antagonists are tested in clinical trials and new agents, "TRPV1 modulators", with fewer side effects are currently developed in experimental studies.
authors.affiliation: EA 6309, maintenance myélinique et neuropathies périphériques, faculté de médecine et pharmacie, Limoges Cedex, France.
authors.forename: Aurore
authors.initials: A
authors.lastname: Danigo
authors.forename: Laurent
authors.initials: L
authors.lastname: Magy
authors.forename: Claire
authors.initials: C
authors.lastname: Demiot
mesh_terms: D000818:Animals; D002986:Clinical Trials as Topic; D004195:Disease Models, Animal; D006801:Humans; D009437:Neuralgia / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D050916:TRPV Cation Channels / Q000037:antagonists & inhibitors* / Q000502:physiology
chemical_list: D050916:TRPV Cation Channels; C494482:TRPV1 protein, human